BRAF V600E disrupts AZD6244-induced abrogation of negative feedback pathways between extracellular signal-regulated kinase and Raf proteins.

@article{Friday2008BRAFVD,
  title={BRAF V600E disrupts AZD6244-induced abrogation of negative feedback pathways between extracellular signal-regulated kinase and Raf proteins.},
  author={Bret B. Friday and Chunrong Yu and Grace Kho Dy and Paul David Smith and Liang Wang and Stephen N. Thibodeau and Araba A. Adjei},
  journal={Cancer research},
  year={2008},
  volume={68 15},
  pages={6145-53}
}
AZD6244 (ARRY 142886) is a potent and selective mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) kinase (MEK) inhibitor currently in early clinical trials. We examined the activity of AZD6244 in a panel of non-small cell lung cancer and a panel of cell lines representing many cancer types using in vitro growth assays. AZD6244 induced G(0)-G(1) cell cycle arrest in sensitive cell lines that primarily included cells containing the BRAF V600E mutation. In these… CONTINUE READING